U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H27ClO7
Molecular Weight 450.9101
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMPAGLIFLOZIN

SMILES

c1cc(ccc1Cc2cc(ccc2Cl)[C@@]3([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(CO)O3)O)O)O)O[C@@]4([H])CCOC4

InChI

InChIKey=OBWASQILIWPZMG-QZMOQZSNSA-N
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=21985634; https://www.boehringer-ingelheim.com/press-release/jardiance-empagliflozin-be-studied-treatment-people-chronic-heart-failure

Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor designed for the treatment of type 2 diabetes mellitus. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Empagliflozin interacts with diuretics, blood presure medicine and insulin. Jardiance reduces the risk of cardiovascular death in diabetes patients at high cardiovascular risk.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.1 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
JARDIANCE

Approved Use

JARDIANCE is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Launch Date

1.40685122E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
259 nM
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMPAGLIFLOZIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
687 nM
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMPAGLIFLOZIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1870 nM × h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMPAGLIFLOZIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
4740 nM × h
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMPAGLIFLOZIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.4 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMPAGLIFLOZIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13.8%
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMPAGLIFLOZIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >1000 uM]
no [IC50 >1000 uM]
no [IC50 >150 uM]
no [IC50 >150 uM]
no [IC50 >150 uM]
no [IC50 >150 uM]
no [IC50 >150 uM]
no
no
no
no
no
no
no
no
no
weak [IC50 114.1 uM]
weak [IC50 1399 uM]
weak [IC50 295 uM]
weak [IC50 45.2 uM]
weak [IC50 58.6 uM]
weak [IC50 71.8 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
2014 Jun
Empagliflozin for the treatment of Type 2 diabetes.
2014 May
Empagliflozin for the treatment of type 2 diabetes.
2014 Nov
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
2015 Jul
Patents

Sample Use Guides

The recommended dose of JARDIANCE is 10 mg once daily in the morning, taken with or without food. In patients tolerating JARDIANCE, the dose may be increased to 25 mg In patients with volume depletion, correcting this condition prior to initiation of JARDIANCE is recommended. Assessment of renal function is recommended prior to initiation of JARDIANCE and periodically thereafter. JARDIANCE should not be initiated in patients with an eGFR less than 45 mL/min/1.73 m^2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73 m^2. JARDIANCE should be discontinued if eGFR is persistently less than 45 mL/min/1.73 m^2.
Route of Administration: Oral
In in vitro experiments empagliflozin is used at a concentration of 100 nM and 500 nM based on recommendations by Boehringer-Ingelheim as these doses effectively and selectively block SGLT2 without significant inhibition of SGLT1.
Name Type Language
EMPAGLIFLOZIN
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
EMPAGLIFLOZIN COMPONENT OF GLYXAMBI
Brand Name English
EMPAGLIFLOZIN [USAN]
Common Name English
D-GLUCITOL, 1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-TETRAHYDRO-3-FURANYL)OXY)PHENYL)METHYL)PHENYL)-, (1S)-
Common Name English
TRIJARDY XR COMPONENT EMPAGLIFLOZIN
Brand Name English
(1S)-1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-OXAN-3-YL)OXY)PHENYL)METHYL)PHENYL)-D-GLUCITOL
Common Name English
BI-10773
Code English
EMPAGLIFLOZIN COMPONENT OF TRIJARDY XR
Brand Name English
EMPAGLIFLOZIN COMPONENT OF SYNJARDY
Brand Name English
EMPAGLIFLOZIN [MI]
Common Name English
GLYXAMBI COMPONENT EMPAGLIFLOZIN
Brand Name English
JARDIANCE
Brand Name English
EMPAGLIFLOZIN [ORANGE BOOK]
Common Name English
EMPAGLIFLOZIN [INN]
Common Name English
BI 10773
Code English
EMPAGLIFLOZIN [WHO-DD]
Common Name English
EMPAGLIFLOZIN [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC A10BD20
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
WHO-ATC A10BD19
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
WHO-VATC QA10BX12
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
WHO-ATC A10BK03
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
WHO-ATC A10BX12
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
NDF-RT N0000187059
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL2107830
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
DRUG BANK
DB09038
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
PUBCHEM
11949646
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
EVMPD
SUB35915
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
FDA UNII
HDC1R2M35U
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
LACTMED
Empagliflozin
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
RXCUI
1545653
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY RxNorm
NDF-RT
N0000187058
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY Sodium-Glucose Transporter 2 Inhibitors [MoA]
CAS
864070-44-0
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
INN
9398
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
IUPHAR
4754
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
DRUG CENTRAL
4830
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
MESH
C570240
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
MERCK INDEX
M11910
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY
WIKIPEDIA
Empagliflozin
Created by admin on Fri Jun 25 20:33:52 UTC 2021 , Edited by admin on Fri Jun 25 20:33:52 UTC 2021
PRIMARY